Amundi Portfolio holdings
Amundi, established in 2010 through the merger of Crédit Agricole and Société Générale’s asset management arms, is Europe’s largest asset management firm, headquartered in Paris, France, overseeing €2.2 trillion ($2.3 trillion USD) in assets as of late 2024. Serving institutional clients, financial advisors, and retail investors across 35 countries, Amundi offers a broad spectrum of investment solutions, including active and passive funds, ETFs, and sustainable investing options, with a strong focus on cost efficiency and ESG (environmental, social, governance) principles. The firm’s growth has been fueled by strategic acquisitions, such as Pioneer Investments in 2017 and Lyxor in 2021, enhancing its global reach and expertise in index tracking and alternatives. Majority-owned by Crédit Agricole, Amundi combines French financial heritage with a modern, client-centric approach, maintaining a dominant position in Europe while expanding in Asia and the Americas.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Freeport-McMoran
FCX
|
+$302M |
| 2 |
Advanced Micro Devices
AMD
|
+$270M |
| 3 |
Cardinal Health
CAH
|
+$257M |
| 4 |
Adobe
ADBE
|
+$221M |
| 5 |
Visa
V
|
+$218M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$257M |
| 2 |
Bank of America
BAC
|
+$245M |
| 3 |
Stanley Black & Decker
SWK
|
+$240M |
| 4 |
Coca-Cola
KO
|
+$232M |
| 5 |
Cisco
CSCO
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.38% |
| 2 | Healthcare | 15.51% |
| 3 | Financials | 12.11% |
| 4 | Consumer Discretionary | 11.09% |
| 5 | Industrials | 8.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1301
iShares JPMorgan EM Local Currency Bond ETF
LEMB
$749M
| $141K | ﹤0.01% |
4,300
-54,900
| -93% | -$1.93M |
|
1302
Pacira BioSciences
PCRX
$1.02B
| $139K | ﹤0.01% |
2,635
| – | – |
|
1303
MSC Industrial Direct
MSM
$7.02B
| $138K | ﹤0.01% |
1,900
-2,800
| -60% | -$230K |
|
1304
SouthState Bank Corp
SSB
$10.3B
| $138K | ﹤0.01% |
1,881
-904
| -32% | -$70.5K |
|
1305
Axsome Therapeutics
AXSM
$12.4B
| $135K | ﹤0.01% |
+3,053
| New | +$96.6K |
|
|
FOLD
1306
DELISTED
Amicus Therapeutics
FOLD
| $135K | ﹤0.01% |
12,280
| – | – |
|
1307
STAAR Surgical
STAA
$1.16B
| $135K | ﹤0.01% |
1,848
| – | – |
|
1308
Mercury Systems
MRCY
$6.2B
| $134K | ﹤0.01% |
2,133
| – | – |
|
|
AVID
1309
DELISTED
Avid Technology Inc
AVID
| $134K | ﹤0.01% |
5,080
-405
| -7% | -$11.8K |
|
|
GBT
1310
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $132K | ﹤0.01% |
3,802
-370
| -9% | -$10.8K |
|
1311
BridgeBio Pharma
BBIO
$16.5B
| $131K | ﹤0.01% |
13,866
+8,453
| +156% | +$70.7K |
|
1312
Revolution Medicines
RVMD
$40.2B
| $131K | ﹤0.01% |
+5,611
| New | +$109K |
|
|
AXON
1313
Axon Enterprise
AXON
$40.5B
| $130K | ﹤0.01% |
1,424
-1,634
| -53% | -$173K |
|
1314
KRONOS Worldwide
KRO
$761M
| $130K | ﹤0.01% |
8,000
| – | – |
|
1315
Novavax
NVAX
$1.23B
| $130K | ﹤0.01% |
2,524
-29,250
| -92% | -$1.52M |
|
1316
Krystal Biotech
KRYS
$9.88B
| $126K | ﹤0.01% |
+1,762
| New | +$110K |
|
1317
Xencor
XNCR
$1.44B
| $123K | ﹤0.01% |
3,995
| – | – |
|
1318
Rapid7
RPD
$634M
| $121K | ﹤0.01% |
1,785
| – | – |
|
1319
Five Below
FIVE
$11.2B
| $118K | ﹤0.01% |
1,015
| – | – |
|
1320
Freshpet
FRPT
$2.83B
| $118K | ﹤0.01% |
2,571
+1,014
| +65% | +$78.2K |
|
1321
ImmunityBio
IBRX
$7.44B
| $118K | ﹤0.01% |
+26,714
| New | +$107K |
|
1322
Semtech
SMTC
$11.7B
| $116K | ﹤0.01% |
2,162
-846
| -28% | -$51K |
|
|
SPTN
1323
DELISTED
SpartanNash
SPTN
| $116K | ﹤0.01% |
3,758
+3,159
| +527% | +$105K |
|
1324
Trupanion
TRUP
$1.05B
| $116K | ﹤0.01% |
1,869
| – | – |
|
1325
Sprouts Farmers Market
SFM
$7.04B
| $115K | ﹤0.01% |
4,309
+564
| +15% | +$15.7K |
|
Similar funds
Amundi's Q2 2022 Portfolio in Review
As of Q2 2022, Amundi held 1,750 positions worth $125B, down 16% from $148B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Amundi's Q2 2022 filing shows 104 new, 631 increased, 657 reduced and 91 closed positions. Its largest new stake was iShares Core S&P 500 ETF: 188,190 shares worth $71.5M. The largest sale was Procter & Gamble, an estimated $257M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
- Amundi's largest Q2 2022 buy was iShares Core S&P 500 ETF: 188,190 shares worth $71.5M.
- Amundi added most to Freeport-McMoran in Q2 2022, an estimated $302M increase.
- Amundi's biggest Q2 2022 reduction was Procter & Gamble, cutting an estimated $257M.
- Amundi fully exited Cerner Corp in Q2 2022, selling an estimated $152M.
- Amundi's ten largest holdings make up 18% of its $125B portfolio in Q2 2022.
- Amundi opened 104 new positions and closed 91 in Q2 2022.
- Amundi's portfolio value fell 16% quarter-over-quarter to $125B.
Based on Amundi's 13F filing for Q2 2022, filed 15 Aug 2022.